Pandemic Darlings The pandemic economy, in original documents
Home Form 4: Sorrento Therapeutics, Inc. (SRNE), Czerepak Elizabeth, transaction 11/18/2021Search ⌕

Form 4: Sorrento Therapeutics, Inc. (SRNE), Czerepak Elizabeth, transaction 11/18/2021

Summary

A Form 4 for Elizabeth Czerepak, a director of Sorrento Therapeutics, Inc. [SRNE], reporting a stock option (right to buy) acquired on November 18, 2021. The option covers 100,000 shares of common stock at an exercise price of $6.01 and expires 11/18/2031. The footnote states 1/12th of the original shares vests on December 18, 2021 and 1/12th monthly thereafter, subject to continued service to the issuer. No common stock transactions are listed. Henry Ji, Ph.D., signed as attorney-in-fact on 11/18/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Form 4: Sorrento Therapeutics, Inc. (SRNE), Czerepak Elizabeth, transaction 11/18/2021.” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-4-filed2021-11-18-0001209191-21-065539-40496634d8/, SHA-256 558191fcfeb96a78320461a59eaa579a5926c6fcde03f31729026bd005266d92.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * CZEREPAK ELIZABETH (Last) (First) (Middle) C/O SORRENTO THERAPEUTICS, INC. 4955 DIRECTORS PLACE (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | CZEREPAK ELIZABETH | (Last) | (First) | (Middle) | C/O SORRENTO THERAPEUTICS, INC. | 4955 DIRECTORS PLACE | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Sorrento Therapeutics, Inc. [ SRNE ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 11/18/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (right to buy) | $ 6.01 | 11/18/2021 | A | 100,000 | (1) | 11/18/2031 | Common Stock | 100,000 | $ 0.00 | 100,000 | D
Explanation of Responses:
1. 1/12th of the original number of shares subject to the option shall vest on December 18, 2021, and 1/12th of the original number of shares subject to the option shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Remarks:
/s/ Henry Ji, Ph.D., as attorney-in-fact | 11/18/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_SRNE_4_filed2021-11-18_0001209191-21-065539.xml
Size
15,659 bytes
SHA-256
558191fcfeb96a78320461a59eaa579a5926c6fcde03f31729026bd005266d92
Our copy
SEC_SRNE_4_filed2021-11-18_0001209191-21-065539.xml
Original
www.sec.gov
Back to top